Next Article in Journal
Insights into the Microbiome and Antibiotic Resistance Genes from Hospital Environmental Surfaces: A Prime Source of Antimicrobial Resistance
Previous Article in Journal
Efficacy and Experience of Bacteriophages in Biofilm-Related Infections
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 13
Issue 2
10.3390/antibiotics13020126
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex

by
Alicja Sękowska
1,2
1
Microbiology Department, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 9 Maria Skłodowska-Curie St., 85-094 Bydgoszcz, Poland
2
Clinical Microbiology Department, Dr. A. Jurasz University Hospital No. 1, 85-094 Bydgoszcz, Poland
Antibiotics 2024, 13(2), 126; https://doi.org/10.3390/antibiotics13020126
Submission received: 19 December 2023 / Revised: 25 January 2024 / Accepted: 25 January 2024 / Published: 26 January 2024
(This article belongs to the Special Issue Antibiotic Resistance in Antibiotic Producers and Other Bacteria: Genes, Mechanisms, Evolution, and Surveillance)
Browse Figure
Review Reports Versions Notes

Abstract

:
The Klebsiella pneumoniae complex is a commonly isolated bacteria in human infections. These opportunistic pathogens pose a serious threat to public health due to their potential transmission to the human population. Resistance to carbapenems is a significant antimicrobial resistance mechanism, leading to limited therapeutic options. Therefore, the aim of this study was to evaluate the in vitro activity of fosfomycin, colistin, ceftazidime–avibactam, and meropenem–vaborbactam against multidrug-resistant K. pneumoniae complex strains. This study involved 160 strains of Gram-negative rods, comprising 138 K. pneumoniae and 22 K. variicola. The minimal inhibitory concentration of fosfomycin was estimated using the agar dilution method, and for colistin, the microdilution method was employed. Susceptibility to ceftazidime–avibactam and meropenem–vaborbactam was determined using the gradient strip method. All analyzed K. pneumoniae complex isolates produced extended-spectrum β-lactamases, and 60.0% exhibited carbapenemases. The majority of the analyzed strains were susceptible to fosfomycin and colistin (62.5%). Among pandrug-resistant K. pneumoniae complex isolates, the highest susceptibility was observed with colistin (43.9%). Fosfomycin demonstrated good activity against ESβLs- and VIM-positive isolates from this complex. Colistin also exhibited satisfactory in vitro activity against VIM- and KPC-positive isolates from the K. pneumoniae complex. Ceftazidime–avibactam displayed good activity against K. pneumoniae complex strains producing ESβLs, KPC, and OXA enzymes. Additionally, meropenem–vaborbactam showed satisfactory in vitro activity against ESβLs- and KPC-positive isolates from this complex.

1. Introduction

The Klebsiella pneumoniae complex is a common causative bacteria for both community- and hospital-acquired infections. The predominant and frequently isolated species within this complex is K. pneumoniae. The incidence of these bacteria causing severe infections with substantial morbidity and mortality has been steadily rising [1]. Notably, in recent years, Klebsiella variicola has been increasingly identified, particularly in cases of bloodstream infections [2,3]. Both K. pneumoniae and K. variicola are associated with severe infections leading to high mortality rates, especially in immunocompromised patients [1,4]. Furthermore, these bacteria frequently exhibit diverse mechanisms of antimicrobial resistance. For many years, the predominant and critical mechanism of antimicrobial resistance within the K. pneumoniae complex was the production of extended-spectrum β-lactamases (ESβLs). However, in the past decade, more and more reports have appeared describing the identification of strains producing carbapenemases [5]. Strains producing EsβLs and carbapenemases can colonize the gastrointestinal tract of healthy individuals, subsequently leading to serious infections. Within the K. pneumoniae isolates, three classes of carbapenemases are identified: class A (Klebsiella pneumoniae carbapenemases, KPC), class B (metallo-β-lactamases, MβL), and class D (oxacillinases, OXA) [6]. Strains producing KPC enzymes are frequently isolated in the United States and Israel [7]. In Poland, the first KPC-positive K. pneumoniae strain was isolated in 2008. Between 2019 and 2021, the frequency of isolation increased by around 200% and accounted for 18% of all cases. [8,9]. The first MβL-positive K. pneumoniae strain in Poland was isolated in 2006 and identified as the VIM-1 enzyme [10]. Since the isolation of the first strain in Poland, VIM enzymes have been identified in various species, with the two dominant ones being Enterobacter hormaechei and Klebsiella oxytoca. However, in recent years, there has been a shift, and an increase in the frequency of isolation of K. pneumoniae and Escherichia coli strains has been observed [9]. Notably, VIM-positive strains were the only carbapenemase-producing isolates for which no increase was recorded in Poland in 2020–2021. The first NDM-positive strain appeared in Poland in 2012 and rapidly spread to other hospitals, causing local epidemics. In 2021, NDM-positive strains accounted for 73% of all carbapenemase-producing Enterobacterales strains in Poland, reflecting a substantial increase in incidence (of 99%) compared to 2019 [9]. In Poland, the first OXA-48-positive isolate, identified as E. hormaechei subsp. steigerwaltii, was recognized in 2012. Until 2017, OXA-48-positive strains were relatively infrequently isolated in Poland. However, in 2021, there was an observed increase in the frequency of strains with this phenotype by approximately 70% compared to 2019. The OXA-48-like group of carbapenemases includes various enzymes such as OXA-48, OXA-181, OXA-232, OXA-204, OXA-162, and OXA-244 [11]. Although carbapenemases can be produced by all Enterobacterales, K. pneumoniae remains the primary species in which they are identified. According to data from the European Antimicrobial Resistance Surveillance System (EARSS), in Poland, the proportion of K. pneumoniae strains resistant to carbapenems isolated from invasive infections increased from 0.8% in 2012 to 6.4% in 2017 and further rose to 16.8% in 2022 [5]. The prevalence of carbapenem-resistant K. pneumoniae strains in Europe varies, ranging from 0.0% in Finland and Iceland to 72.0% in Greece, according to EARSS data from 2022 [5]. Additionally, strains producing more than one β-lactamase from different groups are increasingly being identified. These include combinations such as ESβLs and carbapenemases or two different carbapenemases. In such scenarios, therapeutic options become highly limited. Information regarding the antimicrobial resistance profile of K. variicola strains is scant, often limited to case reports.
Fosfomycin, colistin, ceftazidime–avibactam, and meropenem–vaborbactam are registered for treating severe infections caused by strains with limited therapeutic alternatives. The inclusion of these antimicrobials is justified for various reasons. Fosfomycin and colistin possess unique and distinct mechanisms of action, exhibiting bactericidal activity against a broad spectrum of bacterial species. Additionally, fosfomycin demonstrates excellent diffusion in body tissues and has low toxicity. While monotherapy with fosfomycin is not recommended for treating infections caused by MβL-producing Enterobacterales, it exhibits synergy with other antimicrobials, such as ceftazidime–avibactam [12,13]. On the other hand, despite its high toxicity, colistin remains a drug of last resort for treating multidrug-resistant (MDR) bacterial infections, including those caused by K. pneumoniae [14,15]. The introduction of new combinations of β-lactams with β-lactamase inhibitors has significantly broadened therapeutic options for treating infections caused by carbapenemase-producing strains. These drugs are deemed safe for patients and exhibit effective tissue penetration. Avibactam, a diazabicyclooctane non-β-lactam, binds covalently and reversibly to β-lactamases. Its crucial advantage lies in its ability to inhibit ESβLs, AmpC β-lactamases, as well as class A and D carbapenemases [16]. Vaborbactam, the first boronic acid β-lactamase inhibitor, belongs to a group known for the reversible and competitive inhibition of serine β-lactamases. It effectively inhibits class A β-lactamases, including KPC carbapenemases, and class C β-lactamases. However, it does not inhibit class B and class D β-lactamases [16].
The objective of this study was to compare the in vitro activity of fosfomycin, colistin, ceftazidime–avibactam, and meropenem–vaborbactam against MDR K. pneumoniae complex, encompassing isolates producing ESβLs and various carbapenemases.

2. Results

2.1. Isolates Collection

The study encompassed 160 K. pneumoniae complex strains, comprising 138 (86.2%) K. pneumoniae and 22 (13.8%) K. variicola. Among these, 146 (91.2%) were obtained from clinical specimens (125 K. pneumoniae and 21 K. variicola), while 14 (8.8%) were isolated from gastrointestinal colonization samples (stool and rectal swab) (13 K. pneumoniae and 1 K. variicola). A total of 72 (45.0%) of the analyzed strains were isolated as monocultures (63 K. pneumoniae and 9 K. variicola).

2.2. Identification of Strains and Antimicrobial Susceptibility Testing

In the mass spectrometry method, all of the K. pneumoniae complex strains exhibited identification values over 2.300, which means reliable identification at the genus and species level.
All of the analyzed K. pneumoniae complex strains were MDR. Among the analyzed isolates, 41 (25.6%) were PDR, and they all belonged to K. pneumoniae species. In the group of PDR strains, 39 (95.1%) produced different carbapenemases and only 2 (4.9%) produced ESβLs enzymes. The detailed data of on susceptibility of K. pneumoniae complex strains to antimicrobials, obtained from Phoenix, are presented in Supplementary Material Table S1.

2.3. Detection of Extended-Spectrum β-Lactamases and Carbapenemases

In the automated method, ESβL production was confirmed for all K. pneumoniae strains (n = 138), and in a double-disc test, it was confirmed for all K. variicola strains (n = 22). In the eazyplex® SuperBug CRE test, 140 of the analyzed isolates produced ESβLs, with 139 strains belonging to the CTX-M1 group and 1 strain producing two ESβLs from groups CTX-M1 and CTX-M9. For 115 of the analyzed isolates (113 K. pneumoniae and 2 K. variicola) resistant to at least one carbapenem, the CIM test was performed. Among these, 96 (60.0%) of K. pneumoniae strains tested positive in the CIM test, indicating the production of carbapenemases. The distribution of carbapenemases included NDM in 40 strains, KPC in 17, VIM in 15, OXA-181 in 7, OXA-48 in 2, and 15 strains producing more than one carbapenemase (multi-carbapenemase strains). None of the K. variicola isolates produced carbapenemases. Detailed data on K. pneumoniae complex strains producing β-lactamases are presented in Table 1.

2.4. MIC Determination

Among the 160 K. pneumoniae complex strains, 100 (62.5%) were susceptible to fosfomycin and colistin, 99 (58.1%) to ceftazidime–avibactam, and 88 (55.0%) to meropenem–vaborbactam. The detailed susceptibility profiles for the specific groups of the analyzed K. pneumoniae complex strains are presented in Figure 1.
In the group of PDR K. pneumoniae isolates (41 isolates), the majority were susceptible to colistin (18, 43.9%), followed by fosfomycin (10, 24.4%), ceftazidime–avibactam (10, 24.4%), and meropenem–vaborbactam (6, 14.6%).
Among the carbapenemase-positive strains (96 isolates), the majority were susceptible to colistin (60, 62.5%), followed by fosfomycin (47, 49.0%), ceftazidime–avibactam (35, 36.5%), and meropenem–vaborbactam (29, 30.2%).
The K. variicola ESβLs-positive strains exhibited the lowest MIC50 and MIC90 values for all tested antimicrobials, with the exception of the MIC50 for colistin, which had the highest value among all analyzed groups. Detailed data on MIC50 and MIC90 values are provided in Table 2.
Fosfomycin, colistin, ceftazidime–avibactam, and meropenem–vaborbactam MICs distributions for the specific groups of strains are presented in Table 3, Table 4 and Table 5.
The MICs of fosfomycin ranged from 4 to >256 mg/L for PDR, carbapenemase-positive, and ESβLs-positive K. pneumoniae isolates, and from 4 to 128 mg/L for K. variicola ESβLs-positive isolates.
The MICs of colistin ranged from 0.25 to >16 mg/L for PDR and carbapenemase-positive K. pneumoniae isolates, from 0.25 to 16 mg/L for ESβLs-positive K. pneumoniae isolates, and from 0.25 to 8 mg/L for K. variicola ESβLs-positive isolates.
The MICs of ceftazidime–avibactam ranged from 0.25 to 256 mg/L for PDR isolates, from 0.38 to 256 mg/L for carbapenemase-positive K. pneumoniae isolates, from 0.047 to 64 mg/L for ESβLs-positive K. pneumoniae isolates, and from 0.047 to 2 mg/L for K. variicola ESβLs-positive isolates. The MICs of meropenem–vaborbactam ranged from 0.064 to 256 mg/L for PDR strains, from 0.032 to >256 mg/L for carbapenemase-positive strains, from 0.032 to >256 mg/L for ESβLs-positive K. pneumoniae strains, and from 0.032 to 2 mg/L for K. variicola ESβLs-positive strains.

3. Materials and Methods

3.1. Bacterial Strains

The study included 160 non-replicated strains of the K. pneumoniae complex isolated from various clinical samples derived from patients at Dr. A. Jurasz University Hospital No. 1 in Bydgoszcz, Poland. These isolates were collected over a one-year period, spanning from 1 October 2022 to 30 September 2023. The strains were obtained through standard diagnostic procedures at the Microbiology Department of Dr. A. Jurasz University Hospital No. 1 in Bydgoszcz, Poland.

3.2. Identification and Susceptibility Testing

Isolate identification was performed using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) on the MALDI TOF Biotyper Microflex LT/SH system (Bruker, Bremen, Germany) with version 7.0.0.1 software. For strains with a value ≥2.300, identification was conducted once, while for isolates with values between 2.000 and 2.299, identification was performed thrice.
Antimicrobial susceptibility tests for all the analyzed strains were conducted using the Phoenix M50 system (Becton Dickinson, NJ, USA) with NMIC-408 panels. The obtained results were automatically interpreted following the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2023 Recommendations (v 13.0) [17]. An isolate was classified as MDR if it demonstrated non-susceptibility to ≥1 agent in >3 antimicrobial categories and as pandrug-resistant (PDR) if it exhibited non-susceptibility to all antimicrobial agents [18]. The definitions of MDR and PDR were determined based on the results obtained from Phoenix.

3.3. Detection of Enzymes

For the detection of ESβLs enzymes in K. pneumoniae strains, the Phoenix M50 System (Becton Dickinson, NJ, USA) with NMIC-408 panels was employed. Meanwhile, for K. variicola isolates, ESβLs enzyme activities were identified using the disc diffusion method, specifically the double-disc synergy test with ceftazidime (30 μg), cefotaxime (30 μg), cefepim (30 μg), and amoxicillin with clavulanic acid (30 μg) (Liofilchem, Abruzzi, Italy). Control strains, including E. coli ATCC 25922 (ESβLs-negative) and K. pneumoniae ATCC 700603 (ESβLs-positive), were utilized. For strains resistant to carbapenems, both the Carbapenem Inactivation Method [19] and eazyplex® SuperBug CRE test (Amplex Diagnostics, Gars-Bahnhof, Germany) were employed. Reference strains for this analysis included K. pneumoniae NCTC 13442 (OXA-positive), K. pneumoniae NCTC 13438 (KPC-positive), K. pneumoniae BAA-2146 (NDM-positive), K. pneumoniae NCTC 13440 (VIM-positive), and K. pneumoniae ATCC 700603 (ESβLs-positive).

3.4. MIC Determination

The determination of the fosfomycin MIC was carried out by dilution in agar using AD Fosfomycin (Liofilchem, Abruzzi, Italy). Fosfomycin concentrations in agar ranged from 0.25 mg/L to 256 mg/L. Breakpoints for fosfomycin were interpreted according to EUCAST Recommendations 2023 (v. 13.0) [17] (MIC ≤ 32 mg/L—susceptible, >32 mg/L—resistant). For colistin, MIC was determined using the microdilution method with the MIC COL test (Inc. Diagnostics, Galanta, Slovakia). Colistin concentrations in the broth ranged from 0.25 mg/L to 16 mg/L. Breakpoints for colistin were interpreted according to EUCAST Recommendations 2023 (v. 13.0) [17] (MIC ≤ 2 mg/L—susceptible; >2 mg/L—resistant). Susceptibility breakpoints for ceftazidime–avibactam and meropenem–vaborbactam were established by the gradient strip method (Liofilchem, Abruzzi, Italy). Ceftazidime–avibactam and meropenem–vaborbactam concentrations in the strip ranged from 0.016 mg/L to 256 mg/L. Breakpoints for ceftazidime–avibactam and meropenem–vaborbactam were interpreted according to EUCAST Recommendations 2023 (v. 13.0) [17] (MIC ≤ 8 mg/L—susceptible; >8 mg/L—resistant). E. coli ATCC 25922 and E. coli NCTC 13846 (mcr-1 positive) were used as reference strains.

4. Discussion

The escalating issue of bacterial resistance to antimicrobials has prompted the exploration of new drugs and the reconsideration of well-established ones. Fosfomycin and colistin, discovered a few decades ago, have regained attention. The introduction of intravenous fosfomycin in 2019, particularly in European countries like Poland, broadened its utility against infections caused by MDR strains. Colistin, despite its historical use, faced limitations due to toxicity after 1970. However, both drugs offer a broad spectrum of activity, encompassing strains producing β-lactamases from classes A to D. While various studies have addressed the activity of fosfomycin and colistin, a notable gap exists concerning isolates from Eastern Europe, including Poland. The results of this study demonstrated that over 62% of the analyzed K. pneumoniae complex strains in Poland were susceptible to fosfomycin. Notably, a prior study by Kowalska-Krochmal et al. [20] on a substantial cohort of Klebsiella spp. isolates (250 strains) from patients with invasive infections in Poland reported a 66.0% susceptibility to fosfomycin, with MIC50 at 32 mg/L and MIC90 at 512 mg/L. In the analyzed group, 86 isolates were ESβLs-positive, 26 were ESβLs- and carbapenemase-positive, and 58 were carbapenemase-positive. The results of this study indicated that fosfomycin exhibited high potency, with over 86% susceptibility, against K. pneumoniae VIM-positive isolates and K. variicola ESβLs-positive isolates. These findings underscore the importance of considering regional variations in antimicrobial susceptibility, and obtained results contribute valuable insights into the efficiency of fosfomycin against specific strains in Poland.
According to research conducted in Turkey [21], 53.2% of Klebsiella spp. isolates were susceptible to fosfomycin. Notably, the highest susceptibility was observed for OXA-48- and NDM-positive strains, with 73.3% being susceptible, while strains producing only NDM enzymes exhibited the lowest susceptibility at 33.3%. In this study, none of the nine analyzed OXA-positive isolates were susceptible to fosfomycin, with only two isolates producing OXA-48 and seven strains producing OXA-181. In contrast, a study by Demirci-Duarte et al. [21] reported that 50.5% of OXA-48-positive Klebsiella spp. isolates (n = 104) were susceptible to fosfomycin. Additionally, Aprile et al. [22] found that 76% of KPC-positive K. pneumoniae strains were susceptible to fosfomycin, while none of the NDM- and OXA-48-positive strains showed susceptibility. However, in this study, the value for KPC-positive strains was slightly lower, around 64%, although the number of strains analyzed was smaller. A further study from Latin America [23] reported varying susceptibility of K. pneumoniae strains to fosfomycin, ranging from 90.9% for strains isolated in Chile to 100% for strains isolated in Mexico, with a total of 601 K. pneumoniae isolates included. For carbapenem-non-susceptible K. pneumoniae strains (183), the susceptibility values were 71.4% and 100%, respectively. On the other hand, Zarakolu et al. [24] reported that 90.7% of carbapenem-susceptible K. pneumoniae isolates and 69.4% of carbapenem-resistant isolates were susceptible to fosfomycin.
The results of this study revealed that over 62% of the analyzed K. pneumoniae complex strains were susceptible to colistin. Comparable findings were reported in Greece [25], where the antimicrobial activity of colistin demonstrated a susceptibility rate of 64% among 392 carbapenem-resistant K. pneumoniae strains. In Poland, Pruss et al. [26] conducted a study on a group of 200 K. pneumoniae isolated from clinical samples. Among the analyzed ESβLs-positive strains, they were all susceptible to colistin. For carbapenemase-positive isolates, the susceptibility varied based on the phenotype. The highest susceptibility to colistin was obtained for KPC-positive isolates (100%), followed by NDM-positive isolates (82.3%), and only 50.0% for OXA-48-positive strains. The results of this study showed that colistin was highly potent (≥80% susceptibility) against KPC-positive and VIM-positive K. pneumoniae isolates. However, the lowest susceptibility to colistin was noted for OXA-positive strains, with only 33.4% susceptibility, including the OXA-48 and OXA-181 strains. Research conducted in European countries, including Poland [27], reported that 95.6% of K. pneumoniae among 4201 isolates were susceptible to colistin, with MIC50/90 values of 1 mg/L, ranging from ≤0.12 mg/L to >4 mg/L. Another study from Spain [28] found that the susceptibility of carbapenemase-producing K. pneumoniae strains to colistin decreased from 86.5% to 68.3% over three years. Interestingly, a substantial difference in colistin MIC90 values was observed among carbapenemase-producing K. pneumoniae isolates in Greece, India, and Poland, with values of 64 mg/L, 32 mg/L, and 8 mg/L, respectively. Meanwhile, colistin MIC50 values were similar, at 1 mg/L, 0.5 mg/L, and 0.75 mg/L, respectively.
There are no data in the literature regarding the frequency of the occurrence of colistin-susceptible K. variicola isolates. However, a few articles describe K. variicola strains resistant to this antimicrobial [29,30]. In a previous study, among 13 K. variicola strains isolated from clinical samples, 46.1% exhibited resistance to colistin (unpublished data).
Ceftazidime–avibactam and meropenem–vaborbactam are combinations of established β-lactams with new β-lactamase inhibitors. These antimicrobials received approval from the US Food and Drug Administration and the European Medicines Agency several years ago. Both ceftazidime–avibactam and meropenem–vaborbactam exhibit activity against strains producing class A and C β-lactamases. Additionally, ceftazidime–avibactam demonstrates efficacy against strains producing class D β-lactamases.
The results of this study demonstrate that ceftazidime–avibactam and meropenem–vaborbactam were highly effective (>88% susceptibility) against K. pneumoniae KPC-positive isolates, as well as K. variicola and K. pneumoniae ESβLs-positive isolates. Previous studies from this medical center [31] have also confirmed the high in vitro activity of ceftazidime–avibactam against K. pneumoniae strains producing ESβLs enzymes. In the cited study, out of four strains producing carbapenemases (two OXA-48 and two KPC), three were susceptible to ceftazidime–avibactam. A study from Latin America [23] found that the susceptibility of K. pneumoniae strains to ceftazidime–avibactam varied from 87.0% for strains isolated in Brazil to 100% for strains isolated in Mexico. For carbapenem-non-susceptible K. pneumoniae strains (n = 183), the values were 83.3% and 100%, respectively, with the lowest value obtained in Colombia at 68.6%. According to research conducted in European countries, including Poland [27], 98.9% of K. pneumoniae of 4201 isolates were susceptible to ceftazidime–avibactam with MIC50 0.12 mg/L and MIC90 1 mg/L, ranging from ≤0.015 mg/L to >128 mg/L. Another study from Pittsburgh [32] noted that the susceptibility of K. pneumoniae strains to ceftazidime–avibactam achieved 79.0%. All of the analyzed isolates were carbapenem-resistant, and 93% of them produced KPC enzymes. In this study, over 35% of carbapenemase-positive K. pneumoniae strains were susceptible to ceftazidime–avibactam. Among KPC-positive strains, all were susceptible to this drug. Additionally, a high percentage of OXA-positive K. pneumoniae strains were susceptible to ceftazidime–avibactam, almost 89%. In contrast, Bianco et al. [33] analyzed susceptibility to selected antimicrobials in seven multi-carbapenemase K. pneumoniae isolates, and none of them were susceptible to ceftazidime–avibactam. Similar results were obtained in this study, including 15 multi-carbapenemase K. pneumoniae strains.
According to research conducted in US medical centers between 2018 and 2022 [34], 97.1% of 7153 K. pneumoniae isolates were susceptible to meropenem–vaborbactam. Another study from Pittsburgh [32] noted that the susceptibility of carbapenem-resistant K. pneumoniae strains to meropenem–vaborbactam reached 99.0%, with MICs ranging from ≤0.015 mg/L to >32 mg/L. The majority of these strains (39%) were KPC-positive. Gaibani et al. [35] noted that 87% of KPC-positive K. pneumoniae strains isolated from bloodstream infections in a hospital in Bologna were susceptible to meropenem–vaborbactam. In this study, over 30% of carbapenemase-positive K. pneumoniae strains were susceptible to meropenem–vaborbactam. Among the KPC-positive strains, all were susceptible to this drug. In contrast, Bianco et al. [33] analyzed susceptibility to selected antimicrobials in multi-carbapenemase K. pneumoniae isolates. Two out of seven strains were susceptible to meropenem–vaborbactam. However, in this study, which included 15 multi-carbapenemase isolates, none of the analyzed K. pneumoniae strains were susceptible to meropenem–vaborbactam.
None of the analyzed K. variicola strains produced carbapenemases, but there are articles in the literature about carbapenemase-positive K. variicola strains that produce NDM, KPC, IMP, or OXA enzymes [36,37,38,39]. Although there are a few reports in the literature assessing the susceptibility of K. variicola isolates to antimicrobials, they did not include fosfomycin or new combinations of β-lactams with β-lactamase inhibitors. The limited number of articles on the susceptibility of K. variicola to antimicrobials may be related to the challenges in identifying this species using automatic methods. Additionally, in the mass spectrometry method, the identification result depends on the number and type of spectra collected in the virtual library, making misidentification to other species within the complex possible.
In the era of increasing bacterial resistance to antimicrobials, rapid identification of carbapenemase-positive strains is a microbiological, clinical, and epidemiological concern. The emergence of MDR isolates often prompts difficult choices, such as using drugs with reduced susceptibility or increasing the drug dose. Therefore, it is crucial to monitor the emergence of resistant strains and quickly detect resistance to both “old” and “new” antimicrobials.
However, this study has some limitations. First, all strains were isolated from patients with symptoms of infection, and antimicrobial susceptibility testing was performed in vitro, making it unknown whether the same results would be obtained in vivo. Second, the strains came from patients in one hospital. Third, all K. variicola isolates in the study exhibited only an ESβL phenotype. Considering these aspects, further research should be continued and its scope expanded.

5. Conclusions

MDR K. pneumoniae complex infections, particularly those involving carbapenemase-producing strains, are becoming increasingly common. Fosfomycin, colistin, ceftazidime–avibactam, and meropenem–vaborbactam appear to be promising antimicrobials for treating infections caused by the MDR and PDR K. pneumoniae complex. The results obtained in this study underscore the importance of identifying carabapenemase. The most prevalent mechanisms of carbapenem resistance were NDM and OXA-181 enzymes.
Based on the obtained results, the in vitro activity of fosfomycin is quite satisfactory against VIM-positive K. pneumoniae isolates and ESβLs-positive K. variicola isolates. Colistin demonstrated the highest in vitro antimicrobial activity against strains producing KPC and VIM carbapenemases. However, new combinations of β-lactams with β-lactamase inhibitors (ceftazidime–avibactam and meropenem–vaborbactam) presented excellent in vitro activity against EsβLs- and KPC-positive isolates. Currently, strains producing more than one carbapenemase pose a significant challenge. The findings of this study indicate that only colistin showed good, but unsatisfactory, in vitro activity against K. pneumoniae complex strains. Therefore, the susceptibility of strains to any antimicrobial agents is not constant over time and should be monitored continuously.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/antibiotics13020126/s1, Table S1: The susceptibility to antimicrobials K. pneumoniae complex strains.

Funding

This research was financially supported by Nicolaus Copernicus University funds for the basic research activity of the Microbiology Department Ludwik Rydygier Collegium Medicum in Bydgoszcz, Poland.

Institutional Review Board Statement

The data collected were obtained during a routine diagnostic procedure applied in Microbiology Department of University Hospital No. 1 in Bydgoszcz, Poland. Therefore, the Institutional Review Board Statement and Bioethical Commission Agreement were waived due to the fact that the research was made anonymously.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available on a reasonable request from the corresponding author.

Conflicts of Interest

The author declares no conflicts of interest.

References

  1. Karampatakis, T.; Tsergouli, K.; Behzadi, P. Carbapenem-Resistant Klebsiella pneumoniae: Virulence factors, molecular epidemiology and latest updates in treatment options. Antibiotics 2023, 12, 234. [Google Scholar] [CrossRef] [PubMed]
  2. Maatallah, M.; Vading, M.; Kabir, M.H.; Bakhrouf, A.; Kalin, M.; Nauclér, P.; Brisse, S.; Giske, C.G. Klebsiella variicola is a frequent cause of bloodstream infection in the Stockholm area, and associated with higher mortality compared to K. pneumoniae. PLoS ONE 2014, 9, e113539. [Google Scholar] [CrossRef]
  3. Imai, K.; Ishibashi, N.; Kodana, M.; Tarumoto, N.; Sakai, J.; Kawamura, T.; Takeuchi, S.; Taji, Y.; Ebihara, Y.; Ikebuchi, K.; et al. Clinical characteristics in blood stream infections caused by Klebsiella pneumoniae, Klebsiella variicola, and Klebsiella quasipneumoniae: A comparative study, Japan, 2014–2017. BMC Infect. Dis. 2019, 19, 946. [Google Scholar] [CrossRef]
  4. Rodríguez-Medina, N.; Barrios-Camacho, H.; Duran-Bedolla, J.; Garza-Ramos, U. Klebsiella variicola: An emerging pathogen in humans. Emerg. Microbes Infect. 2019, 8, 973–988. [Google Scholar] [CrossRef] [PubMed]
  5. European Antimicrobial Resistance Surveillance Network (EARS-Net). Available online: https://www.ecdc.europa.eu/en/about-us/partnerships-and-networks/disease-and-laboratory-networks/ears-net (accessed on 9 October 2022).
  6. Cantón, R.; Akóva, M.; Carmeli, Y.; Giske, C.G.; Glupczynski, Y.; Gniadkowski, M.; Livermore, D.M.; Miriagou, V.; Naas, T.; Rossolini, G.M.; et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 2012, 18, 413–431. [Google Scholar] [CrossRef]
  7. Oelschlaeger, P.; Ai, N.; DuPrez, K.T.; Welsh, W.J.; Toney, J.H. Evolving carbapenemases: Can medicinal chemists advance one step ahead of the coming storm? (Perspective). J. Med. Chem. 2010, 53, 3013–3027. [Google Scholar] [CrossRef]
  8. Baraniak, A.; Izdebski, R.; Herda, M.; Fiett, J.; Hryniewicz, W.; Gniadkowski, M.; Kern-Zdanowicz, I.; Filczak, K.; Łopaciuk, U. Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland. Antimicrob. Agents Chemother. 2009, 53, 4565–4567. [Google Scholar] [CrossRef] [PubMed]
  9. Rekomendacje: Pałeczki Enterobacterales Wytwarzające Karbapenemazy (CPE)—Epidemiologia, Diagnostyka, Leczenie i Profilaktyka Zakażeń, 2022—Narodowy Program Ochrony Antybiotyków. Available online: https://www.antybiotyki.edu.pl/rekomendacje-paleczki-enterobacterales-wytwarzajace-karbapenemazy-cpe-epidemiologia-diagnostyka-leczenie-i-profilaktyka-zakazen-2022 (accessed on 22 February 2023).
  10. Sękowska, A.; Gospodarek, E.; Kruszyńska, E.; Hryniewicz, W.; Gniadkowski, M.; Duljasz, W.; Kusza, K.; Wawrzyniak, K. First isolation of metallo-beta-lactamase producing Klebsiella pneumoniae strain in Poland. Anestezjol. Intensywna Ter. 2010, 42, 27–30. [Google Scholar]
  11. Pitout, J.D.D.; Peirano, G.; Kock, M.M.; Strydom, K.-A.; Matsumura, Y. The global ascendency of OXA-48-type carbapenemases. Clin. Microbiol. Rev. 2019, 33, e00102-19. [Google Scholar] [CrossRef]
  12. Mikhail, S.; Singh, N.B.; Kebriaei, R.; Rice, S.A.; Stamper, K.C.; Castanheira, M.; Rybak, M.J. Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2019, 63, e00779-19. [Google Scholar] [CrossRef]
  13. Suich, J.; Mawer, D.; van der Woude, M.; Wearmouth, D.; Burns, P.; Smeets, T.; Barlow, G. Evaluation of in vitro activity of fosfomycin, and synergy in combination, in Gram-negative bloodstream infection isolates in a UK Teaching Hospital. J. Med. Microbiol. 2022, 71, 001524. [Google Scholar] [CrossRef]
  14. Huang, P.-H.; Chen, W.-Y.; Chou, S.-H.; Wang, F.-D.; Lin, Y.-T. Risk Factors for the development of colistin resistance during colistin treatment of carbapenem-resistant Klebsiella pneumoniae infections. Microbiol. Spectr. 2022, 10, e0038122. [Google Scholar] [CrossRef]
  15. Hao, L.; Yang, X.; Chen, H.; Mo, Z.; Li, Y.; Wei, S.; Zhao, Z. Molecular characteristics and quantitative proteomic analysis of Klebsiella pneumoniae strains with carbapenem and colistin resistance. Antibiotics 2022, 11, 1341. [Google Scholar] [CrossRef] [PubMed]
  16. Tompkins, K.; van Duin, D. Treatment for Carbapenem-resistant Enterobacterales infections: Recent advances and future directions. Eur. J. Clin. Microbiol. Infect. Dis. 2021, 40, 2053–2068. [Google Scholar] [CrossRef]
  17. Eucast: EUCAST. Available online: https://www.eucast.org/ (accessed on 3 October 2023).
  18. Magiorakos, A.-P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012, 18, 268–281. [Google Scholar] [CrossRef]
  19. van der Zwaluw, K.; de Haan, A.; Pluister, G.N.; Bootsma, H.J.; de Neeling, A.J.; Schouls, L.M. The Carbapenem Inactivation Method (CIM), a simple and low-cost alternative for the Carba NP Test to assess phenotypic carbapenemase activity in Gram-negative rods. PLoS ONE 2015, 10, e0123690. [Google Scholar] [CrossRef] [PubMed]
  20. Kowalska-Krochmal, B.; Mączyńska, B.; Rurańska-Smutnicka, D.; Secewicz, A.; Krochmal, G.; Bartelak, M.; Górzyńska, A.; Laufer, K.; Woronowicz, K.; Łubniewska, J.; et al. Assessment of the susceptibility of clinical Gram-negative and Gram-positive bacterial strains to fosfomycin and significance of this antibiotic in infection treatment. Pathogens 2022, 11, 1441. [Google Scholar] [CrossRef]
  21. Demirci-Duarte, S.; Unalan-Altintop, T.; Gulay, Z.; Sari Kaygisiz, A.N.; Cakar, A.; Gur, D. In Vitro susceptibility of OXA-48, NDM, VIM and IMP enzyme-producing Klebsiella spp. and Escherichia coli to fosfomycin. J. Infect. Dev. Ctries. 2020, 14, 394–397. [Google Scholar] [CrossRef]
  22. Aprile, A.; Scalia, G.; Stefani, S.; Mezzatesta, M.L. In Vitro fosfomycin study on concordance of susceptibility testing methods against ESBL and carbapenem-resistant Enterobacteriaceae. J. Glob. Antimicrob. Resist. 2020, 23, 286–289. [Google Scholar] [CrossRef] [PubMed]
  23. Appel, T.M.; Mojica, M.F.; De La Cadena, E.; Pallares, C.J.; Radice, M.A.; Castañeda-Méndez, P.; Jaime-Villalón, D.A.; Gales, A.C.; Munita, J.M.; Villegas, M.V. In Vitro susceptibility to ceftazidime/avibactam and comparators in clinical isolates of Enterobacterales from Five Latin American Countries. Antibiotics 2020, 9, 62. [Google Scholar] [CrossRef]
  24. Zarakolu, P.; Eser, Ö.K.; Otlu, B.; Gürpınar, Ö.; Özakın, C.; Akalın, H.; Köksal, İ.; Ünal, S. In-Vitro activity of fosfomycin against Escherichia coli and Klebsiella pneumoniae bloodstream isolates and frequency of OXA-48, NDM, KPC, VIM, IMP types of carbapenemases in the carbapenem-resistant groups. J. Chemother. 2022, 34, 235–240. [Google Scholar] [CrossRef]
  25. Galani, I.; Adamou, P.; Karaiskos, I.; Giamarellou, H.; Souli, M. Evaluation of ComASPTM Colistin (formerly SensiTestTM Colistin), a commercial broth microdilution-based method to evaluate the colistin minimum inhibitory concentration for carbapenem-resistant Klebsiella pneumoniae Isolates. J. Glob. Antimicrob. Resist. 2018, 15, 123–126. [Google Scholar] [CrossRef]
  26. Pruss, A.; Kwiatkowski, P.; Masiuk, H.; Jursa-Kulesza, J.; Bilska, I.; Lubecka, A.; Cettler, M.; Roszkowska, P.; Dołęgowska, B. Analysis of the prevalence of colistin resistance among clinical strains of Klebsiella pneumoniae. Ann. Agric. Environ. Med. 2022, 29, 518–522. [Google Scholar] [CrossRef]
  27. Kazmierczak, K.M.; de Jonge, B.L.M.; Stone, G.G.; Sahm, D.F. In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European Countries: INFORM Global Surveillance 2012–15. J. Antimicrob. Chemother. 2018, 73, 2782–2788. [Google Scholar] [CrossRef]
  28. Pena, I.; Picazo, J.J.; Rodríguez-Avial, C.; Rodríguez-Avial, I. Carbapenemase-producing Enterobacteriaceae in a Tertiary Hospital in Madrid, Spain: High percentage of colistin resistance among VIM-1-producing Klebsiella pneumoniae ST11 isolates. Int. J. Antimicrob. Agents 2014, 43, 460–464. [Google Scholar] [CrossRef]
  29. Lu, Y.; Feng, Y.; McNally, A.; Zong, Z. Occurrence of colistin-resistant hypervirulent Klebsiella variicola. J. Antimicrob. Chemother. 2018, 73, 3001–3004. [Google Scholar] [CrossRef] [PubMed]
  30. Kim, S.J.; Jo, J.; Ko, K.S. Lipid A modification-induced colistin-resistant Klebsiella variicola from healthy adults. J. Med. Microbiol. 2023, 72, 001680. [Google Scholar] [CrossRef] [PubMed]
  31. Sękowska, A. Wrażliwość wielolekoopornych szczepów Klebsiella pneumoniae na połączenie ceftazydymu z awibaktamem. Forum Zakażeń 2019, 10, 269–273. [Google Scholar] [CrossRef]
  32. Wilson, W.R.; Kline, E.G.; Jones, C.E.; Morder, K.T.; Mettus, R.T.; Doi, Y.; Nguyen, M.H.; Clancy, C.J.; Shields, R.K. Effects of KPC variant and porin genotype on the in vitro activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae. Antimicrob. Agents Chemother. 2019, 63, e02048-18. [Google Scholar] [CrossRef] [PubMed]
  33. Bianco, G.; Boattini, M.; Comini, S.; Casale, R.; Iannaccone, M.; Cavallo, R.; Costa, C. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 Era. Eur. J. Clin. Microbiol. Infect. Dis. 2022, 41, 573–580. [Google Scholar] [CrossRef] [PubMed]
  34. Sader, H.S.; Mendes, R.E.; Duncan, L.; Kimbrough, J.H.; Carvalhaes, C.G.; Castanheira, M. Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018–2022). Diagn. Microbiol. Infect. Dis. 2023, 106, 115945. [Google Scholar] [CrossRef] [PubMed]
  35. Gaibani, P.; Lombardo, D.; Bussini, L.; Bovo, F.; Munari, B.; Giannella, M.; Bartoletti, M.; Viale, P.; Lazzarotto, T.; Ambretti, S. Epidemiology of meropenem/vaborbactam resistance in KPC-producing Klebsiella pneumoniae causing bloodstream infections in Northern Italy, 2018. Antibiotics 2021, 10, 536. [Google Scholar] [CrossRef] [PubMed]
  36. Camargo, C.H.; Yamada, A.Y.; de Souza, A.R.; Reis, A.D.; Santos, M.B.N.; de Assis, D.B.; de Carvalho, E.; Takagi, E.H.; Cunha, M.P.V.; Tiba-Casas, M.R. Genomic diversity of NDM-producing Klebsiella species from Brazil, 2013–2022. Antibiotics 2022, 11, 1395. [Google Scholar] [CrossRef] [PubMed]
  37. Ge, H.; Qiao, J.; Xu, H.; Liu, R.; Zhao, J.; Chen, R.; Li, C.; Chen, M.; Guo, X. Emergence of OXA-484-producing Klebsiella variicola in China. IDR 2023, 16, 1767–1775. [Google Scholar] [CrossRef]
  38. Huang, L.; Fu, L.; Hu, X.; Liang, X.; Gong, G.; Xie, C.; Zhang, F.; Wang, Y.; Zhou, Y. Co-occurrence of Klebsiella variicola and Klebsiella pneumoniae both carrying bla KPC from a respiratory Intensive Care Unit Patient. Infect. Drug Resist. 2021, 14, 4503–4510. [Google Scholar] [CrossRef]
  39. Zurfluh, K.; Poirel, L.; Nordmann, P.; Klumpp, J.; Stephan, R. First detection of Klebsiella variicola producing OXA-181 carbapenemase in fresh vegetable imported from Asia to Switzerland. Antimicrob. Resist. Infect. Control. 2015, 4, 38. [Google Scholar] [CrossRef]
Antibiotics 13 00126 g001
Figure 1. Susceptibility to selected antimicrobials of K. pneumoniae complex (n = 160).
Figure 1. Susceptibility to selected antimicrobials of K. pneumoniae complex (n = 160).
Antibiotics 13 00126 g001
Table 1. β-lactamases produced by K. pneumoniae complex strains (n = 160).
Table 1. β-lactamases produced by K. pneumoniae complex strains (n = 160).
Enzymes Produced by Klebsiella pneumoniae Complex Strains (n = 160)
OXA-48-, CTX-M1-positive K. pneumoniae strains (n = 2)
OXA-181-, CTX-M1-positive K. pneumoniae strains (n = 7)
KPC-, CTX-M1-positive K. pneumoniae strains (n = 12)
KPC-positive K. pneumoniae strains (n = 5)
NDM-, CTX-M1-positive K. pneumoniae strains (n = 33)
NDM-positive K. pneumoniae strains (n = 7)
VIM-, CTX-M1-positive K. pneumoniae strains (n = 7)
VIM-positive K. pneumoniae strains (n = 8)
NDM-, OXA-181-, CTX-M1-positive K. pneumoniae strains (n = 13)
NDM-, OXA-181-, CTX-M1-, CTX-M9-positive K. pneumoniae strains (n = 1)
VIM-, NDM-, CTX-M1-positive K. pneumoniae strains (n = 1)
ESβLs-positive K. pneumoniae strains (n = 42)
ESβLs-positive K. variicola strains (n = 22)
Table 2. MIC50 and MIC90 (mg/L) values for selected antimicrobials.
Table 2. MIC50 and MIC90 (mg/L) values for selected antimicrobials.
AntimicrobialK. pneumoniae Carbapenemase-Positive Strains (n = 96)K. pneumoniae ESβLs-Positive Strains (n = 42)K. variicola ESβLs-Positive Strains (n = 22)
MIC50MIC90MIC50MIC90MIC50 MIC90
Fosfomycin24481232416
Colistin0.7580.541.54
Ceftazidime-
avibactam		161280.7520.50.5
Meropenem-
vaborbactam		241280.251.50.250.5
Table 3. MIC distribution for fosfomycin.
Table 3. MIC distribution for fosfomycin.
MIC Value
(mg/L)		K. pneumoniae Carbapenemase-Positive Strains (n = 96)K. pneumoniae ESβLs-Positive Strains
(n = 42)		K. variicola ESβLs-Positive Strains (n = 22)
4345
8564
1616126
3224106
48100
641720
1281841
256710
>256530
MIC value according to EUCAST breakpoints 2023 (v. 13.0) [17].
Table 4. MIC distribution for colistin.
Table 4. MIC distribution for colistin.
MIC Value
(mg/L)		K. pneumoniae Carbapenemase-Positive Strains (n = 96)K. pneumoniae ESβLs-Positive Strains (n = 42)K. variicola ESβLs-Positive Strains (n = 22)
0.25214
0.529205
12582
2323
81168
161350
>161200
MIC value according to EUCAST breakpoints 2023 (v. 13.0) [17].
Table 5. MICs distribution for ceftazidime–avibactam and meropenem–vaborbactam.
Table 5. MICs distribution for ceftazidime–avibactam and meropenem–vaborbactam.
MIC Value
(mg/L)		K. pneumoniae Carbapenemase-Positive Strains
(n = 96)		K. pneumoniae ESβLs-Positive Strains (n = 42)K. variicola ESβLs-Positive Strains
(n = 22)
CZAMVCZAMVCZAMV
0.032010101
0.047011220
0.064010112
0.094010103
0.125000600
0.19000200
0.25015004
0.38101342
0.5213654
0.75313143
14412331
1.51167001
2866631
3110200
4422300
8131200
12000100
16220000
32420000
48180000
64351000
96120000
128630000
2561618
>25628270200
MIC value according to EUCAST breakpoints 2023 (v. 13.0) [17], CZA: ceftazidime–avibactam, MV: meropenem–vaborbactam.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Sękowska, A. In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex. Antibiotics 2024, 13, 126. https://doi.org/10.3390/antibiotics13020126

AMA Style

Sękowska A. In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex. Antibiotics. 2024; 13(2):126. https://doi.org/10.3390/antibiotics13020126

Chicago/Turabian Style

Sękowska, Alicja. 2024. "In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex" Antibiotics 13, no. 2: 126. https://doi.org/10.3390/antibiotics13020126

APA Style

Sękowska, A. (2024). In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex. Antibiotics, 13(2), 126. https://doi.org/10.3390/antibiotics13020126

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop